The Biogen laboratory that develops nusinersen (Spinraza®) communicated at the annual international Cure SMA conference (which took place in virtual mode from June 10 to 12, 2020) new results from the NURTURE trial, conducted in 25 infants with presymptomatic SMA.
After treatment with nusinersen started before the age of 6 weeks and continued continuously up to 4.8 years for some children:
- 100% of children are alive,
- none require permanent breathing assistance,
- 96% of children are able to walk with assistance.
Initially planned over 5 years, this international trial (but not French) is extended to a total duration of 8 years.
Access Biogen press release from June 10, 2020 : « New results from landmark nurture study show that pre-symptomatic SMA patients treated with Spinraza® (nusinersen) continue to demonstrate sustained benefit from treatment »
